SML0547
Loteprednol Etabonate
≥98% (HPLC)
别名:
(11b,17a)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-Androsta-1,4-diene-17-carboxylic acid chloromethyl ester, CDDD 5604, HGP 1, P 5604
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C24H31ClO7
化学文摘社编号:
分子量:
466.95
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
InChI
1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1
SMILES string
CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl
InChI key
DMKSVUSAATWOCU-HROMYWEYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL, clear (warmed)
storage temp.
−20°C
Quality Level
Gene Information
human ... NR3C1(2908)
Biochem/physiol Actions
Loteprednol Etabonate is a "soft" steroid, typically used in topical applications for inflammatory conditions of the eye. Loteprednol Etabonate is an agonist of both glucocorticoid and mineralcorticoid receptors.
Loteprednol Etabonate is an anti-inflammatory corticosteroid (ophthalmology).
Loteprednol etabonate (LE) is a key site-active corticosteroid. It is produced by structural modifications of prednisolone-related compounds to form an inactive metabolite. Double-masked study states that loteprednol etabonate is used to treat giant papillary conjunctivitis, seasonal allergic conjunctivitis, postoperative inflammation and uveitis. LE has good ocular permeation properties.
Features and Benefits
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Brett P Bielory et al.
Current opinion in allergy and clinical immunology, 10(5), 469-477 (2010-08-20)
Corticosteroids are an effective short-term treatment option for seasonal allergic conjunctivitis (SAC). Their use has been limited due to their side effects and has led to the development of modified 'soft', 'smart' ophthalmic corticosteroid formulations that retain their anti-inflammatory mechanism
Marcus Ang et al.
Cornea, 39(8), 940-945 (2020-05-27)
To describe intraoperative and postoperative complications of Descemet membrane endothelial keratoplasty (DMEK) in Asian eyes. A: prospective comparative study of consecutive cases of DMEK cases between January 2016 and January 2018. A subgroup of consecutive patients were optimized with preoperative
Mesut Erdurmus et al.
Cornea, 28(7), 759-764 (2009-07-04)
The aim of the present study was to evaluate the frequency of steroid-induced intraocular pressure (IOP) elevation and/or glaucoma in patients with keratoconus (KCN) compared with patients with Fuchs endothelial dystrophy after penetrating keratoplasty (PK). A retrospective review of the
John D Sheppard et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 27(1), 23-27 (2010-12-08)
This retrospective, clinical comparative analysis describes differences in clinical signs and symptoms and medication tolerability between those patients who receive topical corticosteroids prior to initiation of topical cyclosporine 0.5% emulsion (tCSA) therapy for chronic dry eye disease (CDED) and those
Edeline Lu et al.
Optometry (St. Louis, Mo.), 82(7), 413-420 (2011-05-06)
The aim of this study was to present a case of a patient who showed a significant increase in intraocular pressure (IOP) with topical administration of loteprednol etabonate 0.2%. A 29-year-old man administered 1 drop of loteprednol etabonate 0.2% (Alrex(®))
商品
We offers many products related to Nuclear Receptors (Steroids) for your research needs.
我们可提供多种核受体（类固醇）相关产品，满足您的各类研究需求。
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持